Failed German price negotiations likely to lead to heavy pan-EU discounts
This article was originally published in Scrip
Companies that fail to thrash out a price with German health insurers following early benefit assessments are likely to end up with prices based on a basket of 80% of Euro countries. Such a move would mean lower prices as even troubled countries like Greece could have an impact on German prices, warns the BPI industry organisation, which represents small to medium sized companies.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.